

Budhu et al. *Journal for ImmunoTherapy of Cancer* 2013, **1**(Suppl 1):P173
<http://www.immunotherapyofcancer.org/content/1/S1/P173>



POSTER PRESENTATION

Open Access

Blockade of Treg derived TGF- β abrogates suppression of effector T cell function within the tumor microenvironment

Sadna Budhu¹, David Schaefer^{1*}, Yongbiao Li¹, Alan Houghton¹, Samuel Silverstein³, Taha Merghoub^{1,2}, Jedd Wolchok^{1,2}

From Society for Immunotherapy of Cancer 28th Annual Meeting
 National Harbor, MD, USA. 8-10 November 2013

Regulatory T cells (Treg) play a role in suppression of anti-melanoma immunity; however, the exact mechanism is poorly understood. Through intravital two photon microscopy, we found that Pmel-1 effectors engage in cell-cell interactions with tumor resident Tregs. To determine if contact between Tregs and T effectors (Teff) hinders killing of tumor cells in vivo, we utilized ex-vivo three-dimensional collagen-fibrin gel cultures of B16 melanoma cells. Collagen-fibrin gel cultures recapitulated the in vivo suppression, rendering the dissociated tumor resistant to killing by in vitro activated antigen specific Teff. In vivo depletion of Tregs in foxp3-DTR mice prior to tumor excision reversed the suppression. Additionally, In vivo modulation of intra-tumor Tregs suppressive function by GITR ligation had a similar effect, leading to ex-vivo tumor killing. Using neutralizing antibodies, we found that blocking TGF- β reversed the suppression. In addition, soluble factors from collagen-fibrin gel tumors do not inhibit killing suggesting that suppression is contact or proximity dependent. The CD8 Teff recovered from these gels exhibit a decrease in Granzyme B expression and an increase in expression of T cell exhaustion marker PD-1. These findings support the conclusion that intra-tumor contact with Tregs during the effector phase of the immune response is responsible for inhibiting anti-melanoma immunity in a TGF- β dependent manner, elucidating a novel way to target intratumoral Tregs.

Authors' details

¹Immunology, MSKCC, New York, NY, USA. ²Medicine, MSKCC, New York, NY, USA. ³Columbia University, New York, NY, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P173

Cite this article as: Budhu et al.: Blockade of Treg derived TGF- β abrogates suppression of effector T cell function within the tumor microenvironment. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P173.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Immunology, MSKCC, New York, NY, USA
 Full list of author information is available at the end of the article